ADMA Biologics, Inc. NGM · ADMA
Price alert —
Sign in to get a one-time email the moment ADMA crosses your price. Free accounts included.
Sign in / create a free accountADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA last traded at $8.38, down 2.4% on the day; that's in the lower part of its 52-week range ($7.21–$18.00). Right now it's dipped below its recent average — a spot where watchers often look for signs the dip is stabilizing.
The next scheduled earnings report (2026-08-05) is the biggest known catalyst on the calendar, and after the recent dip, watch whether the price stops making lower lows before assuming the worst is over.
A quick snapshot built from the data on this page — not investment advice. Always do your own research.
Price is stretched slightly below its normal range — a light stretch — early days, worth watching.
- · KC1 lower stretch — light dip
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · Aligned with weak downtrend
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
Our cash-flow model pegs fair value near $-171.80 (fair range $-172–$12). The model's verdict is “Unknown” and accounting quality screens as Weak. Model estimates only — do your own due diligence.
- ✓ Quick ratio 806.42 (antifragile)
- ✓ Current ratio 6.71 (antifragile)
- ✓ Debt/equity 0.31 (antifragile)
- ✓ Goodwill 1% of assets (organic growth)
- ⚠ Debt exceeds cash
- ⚠ Negative retained earnings
- ⚠ Receivables growing faster than revenue
Price implies ~77% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
ADMA is a $1.9 billion company, priced at 12× last year's earnings, and the stock is trading near the bottom of its 52-week range.
Options idea
See more →Earnings
See more →- Last reported
- 2026-05-06
- EPS (act / est)
- 0.17 / 0.20
- Surprise
- -15.2%
- Next report
- 2026-08-05
About
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (…